SIRT2, in particular, has been shown to deacetylase BARD1 at conserved lysine residues within the RING domain, promoting stability of the BRCA1-BARD1 complex and enabling tumor-suppressive function [85]. The gene discussed is BARD1; the disease is neoplasm.